Primary Objective: To describe the immune response induced by VRVg-2 and Verorab vaccines at D14 and D35 when co-administered with Human Rabies Immunoglobulins (HRIG) at D0, according to the Zagreb (2-1-1) IM regimen in healthy adult subjects. Secondary Objective: Immunogenicity To describe the immune response induced by VRVg-2 and Verorab vaccines at D90 when co-administered with HRIG at D0, according to the Zagreb (2-1-1) IM regimen in healthy adult subjects. Safety To describe the safety profile of VRVg-2 and Verorab vaccines when co administered with HRIG at D0, after each vaccination.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of participants achieving rabies virus neutralizing antibody (RVNA) titer greater than or equal to (≥) 0.5 IU/mL
Timeframe: Day 14 (post-vaccination)
Percentage of participants achieving RVNA titer greater than or equal to (≥) 0.5 IU/mL
Timeframe: Day 35 (post-vaccination)
Number of Participants achieving RVNA titer greater than or equal to (≥) lower limit of quantification
Timeframe: Day 14 (post-vaccination)
Number of Participants achieving RVNA titer greater than or equal to (≥) lower limit of quantification
Timeframe: Day 35 (post-vaccination)
Geometric Mean Titer Ratio (GMTR) of individual RVNA titer: (post-/pre-vaccination)
Timeframe: Day 14 (post-vaccination
Geometric Mean Titer Ratio (GMTR) of individual RVNA titer: (post-/pre-vaccination)
Timeframe: Day 35 (post-vaccination)